Status:
COMPLETED
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer
Lead Sponsor:
Bayer
Conditions:
Carcinoma, Non Small Cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Phase 2 study to investigate the efficacy and tolerability of epothilone ZK 219477 in patients with stage IIIb or stage IV non-small-cell lung cancer.
Detailed Description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Eligibility Criteria
Inclusion
- Non-small-cell lung cancer
- Only one previous chemotherapy with a platinum-containing drug
- Use of highly effective birth control methods in females of child-bearing potential
Exclusion
- No more than 1 previous chemotherapy for advanced disease
- Previous participation in another trial within the last 4 weeks
- Breast feeding
- Active infections
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT00160069
Start Date
August 1 2005
End Date
April 1 2009
Last Update
December 4 2014
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Löwenstein, Baden-Wurttemberg, Germany, 74245
2
Augsburg, Bavaria, Germany, 86156
3
Gauting, Bavaria, Germany, 82131
4
Nuremberg, Bavaria, Germany, 90419